What side effects are associated with this type of intervention?

Common treatments for B-cell malignancies, such as fludarabine, cyclophosphamide, and rituximab, often cause side effects including myelosuppression (leading to increased risk of infection), nausea, vomiting, and fatigue. Targeted therapies like ibrutinib, which inhibit B-cell receptor signaling, can cause diarrhea, bleeding complications, atrial fibrillation, and hypertension. These side effects reflect the impact of these treatments on both cancerous and healthy cells, necessitating careful management and monitoring.

What prior FDA approvals exist?

Several FDA-approved drugs target B-cell malignancies by inhibiting pathways crucial for B-cell proliferation and survival. Ibrutinib and acalabrutinib, both Bruton tyrosine kinase (BTK) inhibitors, disrupt B-cell receptor signaling. Venetoclax, a BCL-2 inhibitor, promotes apoptosis in B-cells. Rituximab, obinutuzumab, and ofatumumab are monoclonal antibodies targeting CD20 on B-cells, leading to cell death. These treatments have shown efficacy in various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

What other types of research exist?

Promising novel alternatives to AC676 for B-cell malignancies include: 1) Bendamustine, a hybrid chemotherapeutic agent with activity in non-Hodgkin's lymphoma (NHL); 2) Flavopiridol and UCN-01, which target the cell cycle; 3) PS-341 (Bortezomib), a proteasome inhibitor with significant activity in multiple myeloma and ongoing studies in NHL and chronic lymphocytic leukemia (CLL); 4) G3139, an antisense oligonucleotide showing early promise; 5) Rituximab and other active antibodies like alemtuzumab, epratuzumab, and Hu1D10; and 6) Radioimmunoconjugates such as (90)Y-ibritumomab tiuxetan and (131)I-tositumomab. These alternatives are in various stages of research and clinical trials, showing potential for treating B-cell malignancies.

← Back to Search

Other

AC676 for B-Cell Malignancies

Phase 1

Recruiting

Research Sponsored by Accutar Biotechnology Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new oral drug, AC676, in patients with blood cancers that have returned or are resistant to treatment. The drug aims to stop cancer cells from growing by targeting and destroying a specific protein they need.

Who is the study for?

This trial is for adults with certain types of B-cell malignancies that have come back or didn't respond to treatment. They must have tried at least two treatments already, or be unable to use standard therapies. People can't join if they've had recent cancer treatments, stem cell transplants, CAR-T therapy (for DLBCL patients), active bleeding issues, or are within a specific timeframe after receiving other specific therapies.

What is being tested?

The study tests AC676 in participants with relapsed/refractory B-cell malignancies. It aims to find the safest dose, understand side effects and how the body processes the drug (pharmacokinetics), and assess its effectiveness against these blood cancers.

What are the potential side effects?

While not explicitly listed here, potential side effects may include reactions related to immune system activation such as fever and fatigue; organ-specific inflammation; infusion-related reactions; blood count changes leading to increased infection risk; and possible impact on liver function.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: AC676 Dose EscalationExperimental Treatment1 Intervention

Participants will receive an assigned dose of AC676 in a 28-days cycle.

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for B Cell Malignancies often target specific pathways crucial for B-cell proliferation and survival. Monoclonal antibodies, such as rituximab, target CD20 on B-cells, leading to their destruction. Small molecule inhibitors like ibrutinib inhibit Bruton's tyrosine kinase (BTK), disrupting B-cell receptor signaling and promoting apoptosis. Combination therapies, such as bendamustine with rituximab, leverage both cytotoxic and immune-mediated mechanisms to enhance efficacy. These targeted approaches are essential for effectively managing B Cell Malignancies, as they can be tailored to disrupt specific pathways involved in the disease, potentially improving outcomes and reducing side effects.

Relapses, treatments and new drugs.Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.